1. P-238Phase 3 (COSMIC-312) study of cabozantinib in combination with atezolizumab vs sorafenib in patients with advanced hepatocellular carcinoma (aHCC) who have not received previous systemic anticancer therapy. (2nd July 2019) Authors: Rimassa, L; Cheng, A; Braiteh, F; Benzaghou, F; Hazra, S; Borgman, A; Sinha, R; Kayali, Z; Zhu, A; Kelley, R Journal: Annals of oncology Issue: Volume 30(2019)Supplement 4 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗